BTPc

(redirected from Breakthrough Pain in Cancer)
AcronymDefinition
BTPcBreakthrough Pain in Cancer (oncology)
BTPcBinary Tree Predictive Coding (compression scheme)
BTPcBanyan Tree Private Collection
BTPcBioTrade Principles and Criteria (UN Conference on Trade and Development)
BTPcBethany Trinity Presbyterian (Singapore)
References in periodicals archive ?
Surgery, chemotherapy and radiotherapy are among cancer treatments but these can cause persistent and breakthrough pain in cancer survivors, 50% of them may experience persistent pain and about 40-86% experienced breakthrough pain as reported in various studies3.
Ashmawi, "Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study," Supportive Care in Cancer, vol.
The product is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Sublingual tablet OX27 is being developed to optimise the treatment of breakthrough pain in cancer patients.
Abstral is a rapidly disintegrating tablet for sublingual (under the tongue) administration of fentanyl intended for the management of breakthrough pain in cancer patients who are already receiving opioid analgesics for their underlying persistent cancer pain.
Abstral is a rapidly-disintegrating tablet for sublingual (under the tongue) administration of fentanyl intended for the management of breakthrough pain in cancer patients who are already receiving opioid analgesics for their underlying persistent cancer pain.
SAN ANTONIO -- A new rapidly acting effervescent formulation of fentanyl appears to be safe and effective when used to treat breakthrough pain in cancer patients.
(2000) Breakthrough pain in cancer patients: New therapeutic approaches to an old challenge.
Abstral is a rapidly-disintegrating, sublingual (under the tongue) rapid acting formulation of fentanyl citrate, a well-established opioid, and is indicated for the management of breakthrough pain in cancer patients.
Assessment and management of breakthrough pain in cancer patients: Current approaches and emerging research.
Abstral (fentanyl) is a rapidly-disintegrating tablet for sub-lingual administration used against breakthrough pain in cancer patients who are already receiving opioid analgesics for their underlying persistent cancer pain.